VAV3 and cancer: Of note, overexpression of Vav3/Vav3.1 was equally pronounced in type 1 (endometrioid) and type 2 (serous/clear cell) cancers (Fig. 1c, d), indicating a common mechanism of Vav3 activation among principal EC sub-entities.